Quick filters:
Open Data
Open Code
Pre-registered
Funding Declared
COI Declared
Open Access
Clear Filters
New dosing schedules of dasatinib for CML and adverse event management.
J Hematol Oncol
(Unknown)
Published: 2009
Dysregulation of CXCL9 and reduced tumor growth in Egr-1 deficient mice.
J Hematol Oncol
(Unknown)
Published: 2009
Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non…
Collins BT; Vahdat S; Erickson K; Collins SP; Suy S; Yu X; Zhang Y; Subramaniam D; Reichner CA; Sarikaya I; Esposito G; Yousefi S; Jamis-Dow C; Banovac F; Anderson ED.
J Hematol Oncol
(Unknown)
Published: 2009
Treatment of stage I seminoma: is it time to change your practice?
J Hematol Oncol
(Unknown)
Published: 2008